BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND PBRM1, BAF180, 55193, PB1, MGC156156, MGC156155 AND Treatment
11 results:

  • 1. Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies.
    Dietz MV; van Kooten JP; Paats MS; Aerts JGVJ; Verhoef C; Madsen EVE; Dubbink HJ; von der Thüsen JH
    ESMO Open; 2023 Aug; 8(4):101600. PubMed ID: 37453150
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Dysregulation of SWI/SNF Chromatin Remodelers in NSCLC: Its Influence on cancer Therapies including Immunotherapy.
    Shi Y; Shin DS
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371564
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Non‑small cell lung cancer carrying pbrm1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB.
    Miao XY; Wu H; Ye BC; Yi QW; Lin FN; Wang YL; Ren CL; Jiang YF; Li A
    Sci Rep; 2022 Dec; 12(1):20734. PubMed ID: 36456601
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Identifying metabolic reprogramming phenotypes with glycolysis-lipid metabolism discoordination and intercellular communication for lung adenocarcinoma metastasis.
    Li X; Tang L; Deng J; Qi X; Zhang J; Qi H; Li M; Liu Y; Zhao W; Gu Y; Qi L; Li X
    Commun Biol; 2022 Mar; 5(1):198. PubMed ID: 35301413
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Pan-cancer landscape of
    Kelly AD; Murugesan K; Kuang Z; Montesion M; Ross JS; Albacker LA; Huang RSP; Lin DI; Demirci U; Creeden J
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815356
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure.
    Lin Z; Huang L; Li S; Gu J; Cui X; Zhou Y
    Sci Rep; 2020 Dec; 10(1):21530. PubMed ID: 33299035
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.
    Shang Y; Li X; Liu W; Shi X; Yuan S; Huo R; Fang G; Han X; Zhang J; Wang K; Dou Z; Zhang Y; Zang A; Zhang L
    Sci Rep; 2020 Nov; 10(1):20243. PubMed ID: 33219256
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response.
    Lund-Andersen C; Nakken S; Nygård S; Fromm B; Aasheim LB; Davidson B; Julsrud L; Abrahamsen TW; Kristensen AT; Dybdahl B; Larsen SG; Hovig E; Flatmark K
    Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30862609
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Prognostic role of BAP-1 and PBRM-1 expression in intrahepatic cholangiocarcinoma.
    Sarcognato S; Gringeri E; Fassan M; Di Giunta M; Maffeis V; Guzzardo V; Cillo U; Guido M
    Virchows Arch; 2019 Jan; 474(1):29-37. PubMed ID: 30377796
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Targeting the oncogenic protein kinase Ciota signalling pathway for the treatment of cancer.
    Fields AP; Frederick LA; Regala RP
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):996-1000. PubMed ID: 17956262
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity.
    Regala RP; Weems C; Jamieson L; Copland JA; Thompson EA; Fields AP
    J Biol Chem; 2005 Sep; 280(35):31109-15. PubMed ID: 15994303
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.